Company Overview
SANUWAVE Health, Inc. operates within the healthcare sector, specifically focusing on the medical devices industry, where it commercializes regenerative medicines utilizing noninvasive ultrasound or shockwaves to stimulate tissue and musculoskeletal repair. This operational focus positions the firm to address a niche market requiring advanced therapeutic technologies that promote biological responses without invasive procedures. The company maintains a workforce of 46 employees, supporting its global reach as it distributes these medical device solutions both within the United States and internationally. With a market capitalization of $170.92M and annual revenue of $41.28M, SANUWAVE Health, Inc. represents a mid-sized entity in its segment, indicating a company that has achieved significant product adoption yet remains in a growth phase relative to its total market valuation. These financial figures suggest a business model where substantial revenue generation is currently outpacing profitability, a common characteristic for specialized medical device firms scaling their commercialization efforts.
Financial Health
The company reported revenue of $41.28M over the trailing twelve months, while net income stood at -$7,044,000, revealing a significant gap that highlights a cost structure where expenses, likely driven by research and development or scaling operations, exceed current earnings. Despite the negative net income, the firm generated an EBITDA of $8.06M, which provides a clearer picture of operational profitability before financing costs and taxes. However, free cash flow was -$34,093,124, indicating that capital expenditures and working capital requirements are currently consuming cash reserves faster than operations generate liquidity. The gross margin stands at 78.3%, suggesting a highly scalable product line with low direct costs of goods sold, while the operating margin of 12.8% indicates reasonable control over overhead relative to revenue. The profit margin is -17.1%, reflecting the impact of significant non-operating expenses or one-time costs that have erided overall profitability despite strong gross efficiency. On the balance sheet, the company holds $9.60M in cash against $24.45M in debt, creating a net debt position, though the debt-to-equity ratio is listed as N/A due to the lack of positive equity. The current ratio of 1.16 suggests that the company has just enough current assets to cover its short-term liabilities, pointing to a liquidity position that requires careful management to avoid cash flow constraints. Return on Equity is N/A because the company does not have positive retained earnings to generate a meaningful return on shareholder equity, whereas Return on Assets is 14.9%, indicating that the company's assets are being utilized efficiently to generate income before interest and taxes.
Valuation Assessment
The trailing P/E ratio is N/A due to the negative net income, while the forward P/E is -1993.00, a metric that implies the market is pricing in significant future earnings recovery but currently lacks a positive earnings base for traditional valuation multiples. The price-to-book ratio is -58.27, which indicates that the market value of the company is significantly below its book value, a situation often seen in growth-stage biotech or medical device firms where intangible assets and future pipeline potential are not fully captured on the balance sheet. The price-to-sales ratio is 4.14, and the EV/EBITDA is 23.05, suggesting that investors are willing to pay a premium for revenue growth and operational cash flow potential even in the absence of current net income. The stock has traded between a 52-week low of $19.55 and a 52-week high of $46.59, meaning the current price sits within a range that reflects market volatility and varying sentiment regarding the company's commercialization progress. With a beta of 1.37, SANUWAVE Health, Inc. exhibits price volatility that is higher than the broader market, indicating that the stock price is likely to swing more sharply in response to general market movements or sector-specific news.
Growth & Income
Revenue growth year-over-year is 22.3%, demonstrating a robust expansion in sales, while earnings growth is N/A because the company has not yet achieved consistent profitability to calculate a year-over-year percentage increase in net income. This divergence implies that the company is prioritizing top-line expansion and market penetration over immediate profit generation, a strategy typical for firms in the regenerative medicine space. The company does not pay a dividend, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning that all available earnings are reinvested back into the business to fund operations and growth initiatives rather than being distributed to shareholders. Consequently, the overall growth and income profile for SANUWAVE Health, Inc. is characterized by aggressive revenue expansion funded by internal cash generation and external financing, with no reliance on dividend income for investors.